InMed Pharmaceuticals Inc.
INM
Last
$1.36
Day
+2.3%
1y
-43.4%
5y
-99.8%
52w
-45.5%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0526d
EMA 21
1.35
EMA 50
1.38
EMA 200
1.47
20d high
-11.6%
5y high
-99.9%
5y range
0th
Positions held
Your positionsINM isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-12
Hold
avoid
Signal
Sell
Target
$1.42
Stop
$1.26
Stop distance
7.3%
Target vs last
+4.4%
Fundamentals
| Market cap | $7.31M | Enterprise value | $5.07M | Trailing P/E | — | Forward P/E | -0.21 |
| PEG | — | Price / book | 6.62 | Beta | 0.93 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -1.6% | ROA | -66.5% | Debt / equity | — |
| Current ratio | 1.37 | Free cash flow | -$3.19M | Analyst recommendation | none | Mean target | — |
| 52w high | $2.40 | 52w low | $0.58 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.8M | $1.1M | $1.3M | — |
| Op margin | — | — | -258.6% | -157.5% | -141.2% | — |
| Net income | -$5.8M | -$3.0M | -$2.0M | -$1.7M | -$1.8M | — |
| Gross margin | — | — | 22.5% | 36.0% | 44.2% | — |
| Gross profit | — | — | $0.2M | $0.4M | $0.6M | $0.2M |
| Operating income | -$3.2M | -$2.8M | -$2.1M | -$1.8M | -$1.8M | — |
- Gross margin 22.5% (was 36% prior quarter).
- Operating margin compressed to -258.6%.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $4.6M | $4.1M | — |
| Op margin | — | — | -176.9% | -202.6% | — |
| Net income | -$12.6M | -$8.2M | -$7.7M | -$7.9M | — |
| Gross margin | — | — | 23.9% | 33.9% | — |
| Gross profit | — | $1.7M | $1.1M | $1.4M | $0.5M |
| Operating income | -$9.9M | -$8.4M | -$8.1M | -$8.4M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-18 · InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
2026-09-09 · InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
2026-07-22 · Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
Price (daily)
Full chart · RSI · MACD · patternsINM · daily-4.3% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin